In March last year, the Centre had banned 344 FDC drugs citing health risks and lack of therapeutic justification.
In its earlier hearing on June 21, the High Court denied interim relief to three pharmaceutical companies – Mankind Pharmaceuticals, Akum Drugs and Pharmaceuticals Ltd and JB Chemicals and Pharma Ltd.
The Delhi High Court will today hear the plea filed by several pharmaceutical companies that sought a stay of a central government notification that banned certain fixed dose combination (FDC) drugs.
The ban covered about 6,000 brands and major pharma houses including Pfizer Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Sanofi India Ltd., Alkem Laboratories Ltd. and Wockhardt Ltd. The ban was imposed following a report by a six-member committee headed by Chandrakant Kokate, vice-chancellor of KLE University, Karnataka.
Proceedings in all high courts against the ban on 344 FDC drugs are stayed by the Supreme Court where the matter is pending.